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Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC) is a progressive 
myocardial disease that primarily affects the right ventricle. It develops predominantly at young 
age, and the first symptom is often sudden cardiac death (SCD) associated with malignant 
ventricular arrhythmia. Diagnosis using standard cardiac assessment may be hampered due 
to slight and nonspecific clinical signs at early stage of the disease, particularly in relatives 
of the patient. Molecular genetic testing can provide more information for clinical decision 
making. Here we report a patient with a clinical diagnosis of ARVC who was found to have 
a new frame shift mutation in the PKP2 gene through molecular genetic testing using Next 
Generation Sequencing methods. Subsequent family assessment showed that all three of the 
proband’s children also carried this mutation. The results of molecular diagnostics allowed us 
to assess the risk of developing ARVC and SCD in relatives of the proband, as well as to set up 
individual cardiac assessment protocols. Results obtained emphasize the importance of family 
screening when a pathogenic mutation is detected in the primary patient, and demonstrate 
the efficiency of genetic testing in cardiological practice.
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Introduction
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC) is a hereditary 
progressive cardiac muscle disease characterized by fibro fatty myocardial dysplasia, ven-
tricular arrhythmia, and sudden cardiac death (SCD) [1]. Predominantly the right ven-
tricular myocardium is affected; left ventricular and biventricular forms are less common 
[2]. The mode of inheritance is autosomal dominant. Thirty to fifty percent of cases have 
a familial distribution, with typical varying expressivity and incomplete age-dependent 
penetrance [1]. The general population frequency is reported to be 1/1000 to 1/10,000 in 
different references [3; 4]. ARVC is a primary cause of SCD among athletes and young 
people [1; 5]. The diagnosis is established according to the Task Force Criteria of the Eu-
ropean Society of Cardiology revised in 2010 (TFC2010) [6].
To date, 14 genes have been reported to be associated with the development of ARVC 
(PKP2, DSP, FLNC, DSC2, DSG2, JUP, TGFB3, TMEM43, LMNA, DES, TTN, PLN, CT-
NNA3, RYR2) [7; 8]. The most frequently found mutations were mutations in the PKP 
gene, which were detected in 10 % to 78 % of patients according to different reports [7; 
9; 10]. “Radical” mutations (in-frame and frame shift insertions/deletions, splice junc-
tion, and nonsense mutations) constitute up to 75 % of all pathogenic variants identi-
fied in ARVC patients [7; 10]. Genetic testing should be recommended to patients with 
definite or potential diagnosis of ARVC (TFC 2010 criteria), as well as to their relatives 
if a pathogenic mutation was detected [11]. The use of conventional methods such as 
PCR-RFLP and Sanger sequencing is time consuming and cost-ineffective compared with 
Next Generation Sequencing (NGS). In Russia, most studies are targeted at hypertrophic 
and restrictive cardiomyopathy [15–17], with insufficient data on ARVC. More detailed 
informationon the etiology, pathogenesis, and clinical course characteristics of the ARVC, 
depending on the genetic variant present, can be found in the previous review article [18; 
21; 22].
Case report
A 56-year-old man (proband) presented with episodes of rapid, uneven heartbeat, 
repeated episodes of general weakness, dizziness, insomnia, death anxiety, and a decline 
in ability to perform daily activities. These symptoms concerned him for many years, and 
over the last few months his general state became worse. The patient had no history of 
arterial hypertension, ischemic heart disease, or hypercholesterolemia. Since the age of 
19 he was experiencing weakness, episodes of dizziness, and recurrent syncope during 
physical exertion. The family medical history indicated that the eldest son of the proband 
died suddenly at the age of 20 during exercise (sports activity). Ventricular fibrillation 
during cardiopulmonary resuscitation (CPR) resulted in asystole, CPR was ineffective. His 
second son, a 17-year-old, complaints of rapid heartbeat, weakness, and lightheadedness 
associated with stress, but physical exercise is well tolerated. Holter electrocardiogram 
(ECG) monitoring showed no arrhythmias, despite his complaints of rapid heartbeat. 
Other routine methods of cardiological assessment [ECG, echocardiograph (echo-CG), 
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and signal averaged ECG (SAECG)] did not show any deviations from normal values. 
Two younger children of the proband, a daughter (6  years old) and son (4  years old), 
do not have any complaints, and their development and health status indicators are nor-
mal for their age; the results of cardiological assessment (ECG, echo-CG) did not show 
any significant deviations. The proband’s parents, 86-year-old mother and 88-year-old fa-
ther, are alive, their state of health is consistent with their age, and neither had anyclini-
cally proven cardiovascular diseases. The proband’s sister and her children are healthy, 
as well.
The proband underwent a cardiological assessment. Physical examination showed 
right heart dilation and muffled arrhythmic heart tones on auscultation. 
Fig. 1 shows the ECG of the proband, with signs of right (RV) and left (LV) ventricu-
lar myocardial hypertrophy, as well as with specific findings of epsilon wave in leads V1-
V2 and negative T-wave in right-sided chest leads.
Fig. 1. 12-lead ECG of the patient. The epsilon wave is present in chest leads, and best visualized in the 
lead V1.
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Fig. 2. 24-hour Holter monitoring. Paroxysmal monomorphic ventricular tachycardia with a heart rate 
of 141 beats per minute (bpm).
Fig. 3. Signal averaged ECG in the patient. Positivity criteria for late ventricular potentials 
(LVPs) are present.
In the course of 24-hour Holter monitoring (HM) following findings were recorded: 
2653 polymorphic ventricular extrasystoles for a period of 24 hours with regular intraday 
distribution, three short episodes of unstable ventricular tachycardia lasting up to 5 sec-
onds with a wide QRS-complex morphologytypical for complete left bundle branch block, 
and 3451 isolated supraventricular extrasystoles. The HM record fragment containing the 
episode of unstable ventricular tachycardia is presented in Fig. 2.
The results of signal averaged ECG analysis showing late ventricular potentials 
(LVPs) are shown in Fig. 3. The duration of the filtered QRS complex (tot QRSf) is 142 ms. 
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Root mean square voltage of the terminal 40 ms of the filtered QRS complex (RMS40) is 
17 μV. Duration of low-amplitude signals in the terminal filtered QRS complex (LAS40) 
is 39 ms. The presence of all three positivity criteria definitively indicates that the proband 
has LVPs. LVPs reflect delayed myocardial repolarization and often correspond to epsilon 
wave on the standard ECG. 
Transthoracic echo-CG indicates a dilation of all cardiac chambers, predominantly of 
the right ventricular chamber, mild eccentric hypertrophy of the LV myocardium, and a 
decrease in the global left ventricular contractility; LV ejection fraction (EF) by Simpson 
is 31 %. No LV local contractility impairment zones were found. A decrease in the RV con-
tractility [tricuspid annular plane systolic excursion (TAPSE) is 13 mm], thinning of the 
RV wall, and aneurysmal bulging of the RV free wall at the apex were observed. Doppler 
examination showed increased pressure in the right chambers of the heart, stage 2 pul-
monary hypertension (calculatedsystolic pressurein thepulmonary arterywas 45 mm Hg), 
and tricuspid regurgitation due to over distension of the tricuspid annulus bydilated RV. 
Fig. 4 shows the echocardiographic scan with changes in the RV. 
Fig. 4. Echocardiogram of the patient. Parasternal long axis view. 
Significant dilation and spherical configuration of the right ventricle; thinning 
and heterogeneity of its walls are clearly seen.
Contrast enhanced magnetic resonance imaging (MRI) (contrast agent, Gadovist) 
with fat suppression function showed RV dilation, free wall deformation, and no visible 
moderator band. End-diastolic volume of the RV was 347 mL. End-systolic volume of the 
RV was 315 mL. RV ejection fraction constituted 9 %. Significant uneven fat infiltration 
of all of the RV walls, particularly in its basal and apical segments, can be seen. Multiple, 
various in area, occasionally confluent regions of transmural fibrosis of the RV wall are 
visualized. Concordant with detected fibrotic foci, the patient had hypokinesia of all of the 
RV walls with kinetic and dyskinetic zones. Wall aneurysm up to 40 mm in size is clearly 
seen in the basal RV segments, as shown in Fig. 5. In other RV segments, single small an-
eurysms up to 5 mm in size were seen. Double cardiac apex due to enlarged RV is visible, 
as well as dilated LV, but to a lesser extent. End-diastolic volume of the LV is 265 mL. End-
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systolic volume of the LV is 177 mL. LV ejection fraction constituted 33 %. No LV local 
contractility impairment zones were found.
Ischemic heart disease was excluded by coronary angiography: rightcoronary circula-
tion and right coronary artery are visible along the entire length, and the artery is large 
in caliber. The left main coronary artery is seen without defects and is short (up to 5 mm 
in length), and the anterior interventricular artery is visible along the entire length up 
to distal segments and is large in caliber. The circumflex artery is medium in caliber and 
visualized along the entire length with no signs of stenotic lesions. The diagonal branch is 
medium in caliber with no visible stenosis.
Endocardial electrophysiological examination showed no evidence of atrioventricu-
lar dissociation or the presence of an additional atrioventricular connection; no induction 
of atrial arrhythmia was observed. Programmed stimulation of theRV was performed, 
inducing stable ventricular tachycardia from the RV outflow tract with conversion to ven-
tricular flutter. Sinus rhythm was restored by electrical cardioversion.
According to current criteria [6], the patient was diagnosed with ARVC. Three ma-
jor criteria were present (the epsilon wave, inverted T waves on body-surface ECG, and 
aneurysms and RV dilation registered with cardiac MRI and Echo-CG). Moreover, mi-
nor criteria were also present (family history of sudden death, LVPs, unstable ventricular 
tachycardia with characteristic morphology of RV outflow tract, and more than 500 ven-
tricular extra systoles per day).
SCD risk estimation was performed. Due to ventricular tachycardia episodes, synco-
pal conditions, SCD in a first-degree relative under 40 years old, and RV wall aneurysm, 
SCD risk was regarded as very high. Taking all these factors into account, the patient 
was implanted with a cardioverter defibrillator (ICD). Sotalol was prescribed as an anti-
arrhythmic therapy in a daily dose of 160 mg. The patient was recommended to avoid sig-
nificant physical activity, and his children were advised to refrain from competitive sports.
The well-being of the patient remained satisfactory during the 4-year follow-up pe-
riod, with no registered syncopal conditions. Over this period, ICD internal memory 
registered three events of paroxysmal ventricular tachycardia with a heart rate of 150 to 
160 bpm. All three paroxysmal ventricular tachycardia events were terminated by effective 
antitachycardia pacing (ATP) therapy without ICD shocks. 
Fig. 5. Cardiac MR-tomogram. End-diastolic phase. Dilation of the right ventricular cavity. Aneurysmis 
seen inbasalsegments of the right ventricular wall, as well as basal segment hypokinesia (arrows). 
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Fig. 6. Pedigree. The proband is indicated by the arrow; solid black-filled shapes represent patients with 
ARVC TFC+; + represents individuals with c.355delT mutation.
Considering the autosomal dominant inheritance of the disease and the high prob-
ability of SCD, we decided to perform molecular genetic testing of the proband and his 
family. The pedigree is shown in Fig. 6. DNA was isolated using phenol/chloroform ex-
traction from patients’ peripheral blood leukocytes [12]. The assay was performed on the 
MiSeq (Illumina, USA) Next-Generation sequencer using paired-end reads (2×150bp). 
The sample preparation involved selective capture of DNA fragments comprising cod-
ing regions of 46 genes associated with the development of inherited cardiomyopathies, 
including genes PKP2, PLN, DSP, DSC2, DSG2, JUP, TMEM43, DES, TTN, LMNA associ-
ated with the development of the hereditary form of ARVC. A complete list of genes test-
ed is presented on the manufacturer’s website: http://support.illumina.com/downloads/
trusight_cardiomyopathy_product_files.html. The annotation of identified variants was 
performed against all known transcripts of each gene found in the RefSeq database. Clini-
cally relevant variants were confirmed by an alternative method, Sanger sequencing.
A heterozygous deletion c.355delT (NM_004572.3)  in the PKP2 gene (Fig. 7) was 
identified in the proband. This variant was not reported to date in databases or scientific 
literature; it was also absent from the Exome Aggregation Consortium, the Exome Vari-
ant Server, and the 1000 Genomes Project. The PKP2 gene encodes a protein, plakophi-
lin-2, which is involved in desmosome formation. Desmosomes are major components 
of intercellular interactions and are particularly abundant in epidermis and myocardium. 
Defects inintercellular junctions are a major factor leading to ARVC [19]. Thymine dele-
tionat cDNA position 355 results in a frame shift, causing premature chain termination 
p.Y119fs*23 (and eventually leads to non sense-mediated transcript decay or truncated 
protein formation). According to ACMG criteria [13], the identified mutation was classi-
fied as “likely pathogenic.”
Subsequent cascade screening of the family members showed that all three of the 
proband’s children carried this mutation. Cardiological assessment (examination, ECG, 
Echo-CG, and HM ECG) showed no abnormalities, which does not rule out the possi-
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bility of future disease development, as the average age at diagnosis of ARVC is 31 (±13; 
range of 4–64 years) [4]. Based on information obtained, we selected the following moni-
toring algorithm for children of the proband: visiting a cardiologist for standard assess-
ment (including children/parents interviews about events of syncopes, paroxysms, and 
tachyarrhythmias; ECG, echo-CG, 24-hour ECG monitoring) every 2 to 3 years until the 
age of 10 years, and annually after 10 years (screening protocol should include SAECG). If 
any abnormalities are detected, then contrast-enhanced cardiac MRI is indicated. Recom-
mendations also include life style modification (avoiding heavy physical exertions, restric-
tion from competitive sports).
Discussion and conclusion
ARVC is a hereditary progressive myocardial disease with incomplete age-related 
penetrance and variable expressivity. It is inherited in an autosomal dominant pattern, 
often with the first symptom being SCD. We examined a family in whichthe father (with a 
clinical diagnosis of ARVC) and his children (currently asymptomatic) are heterozygous 
carriers of the novel frame shift mutation c.355delT in the PKP2 gene. At the time of this 
study, the proband has a definite clinical diagnosis of ARVC in advanced stage, and he 
was implanted with a cardioverter defibrillator for life-saving reasons. Accordingly, the 
detection of a pathogenic mutation will not influence prognosis and treatment modality. 
Nevertheless, determination of the carrier state is necessary for asymptomatic relatives, 
because it has diagnostic, prognostic, and the rapeutic value. According to existing crite-
ria, identification of a pathogenic mutationis is a major criterion for ARVC diagnosis [6]. 
Moreover, according to data reported in the literature, relatives, who inherited the muta-
tion, have two times the risk of developing ARVC in their lifetime, and eight times the risk 
of developing stable ventricular tachycardia compared with non-carriers [14]. Patients 
carrying this mutation have an increased risk of SCD; therefore, they have a greater need 
for ICD [14]. All children in the studied family inherited the pathogenic mutation from 
their father, which indicates a high risk of ARVC and SCD. Accordingly, preventive meas-
Fig. 7. Electropherogram. Frame shift mutation c.355delT (p.Y119fs*23)  in the PKP2  gene (for the 
R-primer).
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ures are taken (regular cardiological assessment and life style changes) that help to avoid 
the development of the disease, as well as related complications. 
Despite global trends, genetic testing for inherited cardiomyopathy in Russia is rare. 
There were no detailed reports in the literature about molecular genetic confirmation of 
ARVC diagnosis in Russian families. Systemic approach is valuable in diagnostics of car-
diologic pathology [20]. The family case described here proves the efficiency of molecular 
genetic analysis (in particular by Next Generation Sequencing methods) in the practice 
of cardiology. 
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